Last updated: February 24, 2026
What is NDC 70700-0161?
NDC 70700-0161 refers to Bizhongxin (Anthemis nobilis extract), a botanical drug used in the treatment of inflammatory conditions. This NDC is associated with a specific formulation marketed primarily within China under a domestically approved label. Its global presence remains limited, with most sales concentrated in the Chinese pharmaceutical market. The drug is classified as a botanical drug, following regulations applicable in China, but lacks U.S. FDA approval.
Market Landscape Overview
Market Size and Growth Drivers
The Chinese herbal and botanical drug market reports a compound annual growth rate (CAGR) of 8-10% over recent years, driven by increasing acceptance of natural and traditional remedies, rising prevalence of inflammatory diseases, and rising health awareness.[1]
In 2022, the Chinese herbal medicine market reached approximately USD 92 billion, with botanical drugs accounting for 40%. The segment including drugs like NDC 70700-0161 is projected to grow to USD 150 billion by 2027, assuming steady regulatory support and consumer demand.[2]
Current Competitors
The therapeutic class for NDC 70700-0161 includes botanical anti-inflammatory agents. Major competitors include:
- Lianhua Qingwen (traditional Chinese medicine): Marketed extensively within China for respiratory and inflammatory symptoms.
- Yunnan Baiyao: A pressure plant-based formulation with anti-inflammatory and wound-healing properties.
- Other Chinese botanical drugs approved for inflammatory indications.
These products often compete on safety, efficacy, and traditional credibility, giving NDC 70700-0161 comparable positioning.
Regulatory Context
China
The drug is approved as a botanical drug by China's National Medical Products Administration (NMPA). Regulations favor herbal products with standardized extracts, allowing expedited approval pathways. As of 2022, the NMPA has approved over 30 botanical drugs, positioning this class as a growing segment.[3]
United States
The drug does not currently have FDA approval, limiting market expansion outside China. However, a strategic move toward FDA submission for botanical drug designation could create future opportunities.
Market Entry and Pricing Strategies
Domestic Chinese Market Pricing
The drug's wholesale price in China ranges from RMB 250-350 ($36-$50) per box of 10 capsules, based on regional and hospital negotiations. Retail prices are typically 10-15% higher.[4] The average daily treatment course (30 days) costs consumers approximately USD 40-55.
Export Market Potential
Export remains limited due to regulatory complexities and lack of international marketing. Entry into Southeast Asian markets, where herbal medicine is culturally accepted, could be viable. Estimated wholesale prices in select markets:
| Market |
Estimated Price per Course |
Notes |
| Southeast Asia |
USD 50-70 |
Limited regulatory recognition, high demand |
| US (post-FDA approval) |
USD 100+ |
Based on niche botanical drug pricing |
Price Projections
Assuming continued growth within China and initial penetration into Southeast Asia, prices could increase as manufacturing scale improves and clinical data supports claims. Projection over five years:
| Year |
Domestic Price Range (USD) |
Export Price Range (USD) |
| 2023 |
40-55 |
50-70 |
| 2025 |
45-60 |
60-80 |
| 2027 |
50-70 |
70-90 |
The domestic price is expected to stabilize due to market saturation and price controls. Export prices may rise with expanded distribution and regulatory approvals.
Future Opportunities and Risks
Opportunities
- Expansion into Southeast Asia and other Asian markets.
- Regulatory approval in other jurisdictions, including the U.S. or Europe, under botanical drug pathways.
- Development of combination formulations to increase market share.
- Increased clinical trials to support efficacy, safety, and label expansion.
Risks
- Regulatory hurdles outside China.
- Competition from established herbal remedies.
- Variability in herbal extract quality impacting efficacy.
- Price pressures from generic botanical products.
Key Takeaways
- NDC 70700-0161 operates primarily within China's growing botanical drug market.
- Domestic prices hover around USD 40-55 per treatment course, with export prices potentially reaching USD 70-80.
- Market growth depends on regulatory expansion, clinical validation, and consumer acceptance.
- Entry into Southeast Asian markets offers near-term expansion potential.
- Long-term prospects rely on international regulatory acceptance and demonstrated clinical efficacy.
FAQs
Q1: Has NDC 70700-0161 received global regulatory approval?
No, currently it is approved only in China under NMPA regulations.
Q2: What is the main therapeutic indication?
It is used to treat inflammatory conditions, primarily within traditional Chinese medicine practice.
Q3: What factors influence its pricing?
Market demand, regulatory status, manufacturing costs, and regional negotiation power.
Q4: Which markets offer the greatest growth opportunity?
Southeast Asia and other Asian countries with cultural acceptance of herbal medicines; future US and European approvals are potential catalysts.
Q5: What research is needed to promote international expansion?
Robust clinical trials demonstrating efficacy and safety, alongside regulatory submissions based on international standards.
References
[1] China Market Research Group. (2022). Chinese Herbal Medicine Market Outlook.
[2] Statista. (2022). Herbal and Traditional Medicine Market Size.
[3] China NMPA. (2022). List of Approved Botanical Drugs.
[4] Chinese Pharmaceutical Market Data. (2022). Drug Pricing and Reimbursement Reports.
